EWO1 in Persistent Allergic Rhinitis Patients


China Medical University

Status and phase

Phase 3
Phase 2


Rhinitis, Allergic, Perennial


Drug: EWO1

Study type


Funder types




Details and patient eligibility


The aim of this double-blind, randomized, parallel group, placebo-controlled study is to assess the efficacy and safety of EWO1 in patients with moderate to severe perennial allergic rhinitis (AR).

Full description

Allergic rhinitis is a very common medical problem affecting adults and children alike. It has been estimated that 20% to 25% of the world's population suffer from allergic rhinitis, resulting in considerable morbidity - impaired quality of life. In the U.S., there is an estimated $2.4 billion annual medical cost associated with allergic rhinitis. In Taiwan, household dust mites (HDM) are primary allergens causing allergic reactions including allergic rhinitis. The incidence of HDM in Taiwan can be as high as 100%. Df, Dp and Blomia tropicalis (Bt) rank among the top 3 most common household dust mites. Antihistamines remain a major therapy for treatment of allergic rhinitis. Chinese herbs have long been used to treat different allergic and immunologic diseases. YU-PING-FENG-SAN (YPFS) with a formulation that contains 3 herbs [Huangqi (HQ), baizhu (BZ), and fangfeng (FF)] has been reported as one of the effective traditional Chinese medicines for the treatment of recurrent rhinitis. In 3 previous non-placebo controlled clinical studies in perennial rhinitis, it has been demonstrated that by adding Xingyi(XY) to a YPFS formula with CQ, BZ, and FF, additional efficacy benefits can be obtained. The aim of this double-blind, randomized, parallel group, placebo-controlled study is to assess the efficacy and safety of EWO1 in patients with moderate to severe perennial allergic rhinitis. After a 2-week placebo run-in period, patients who satisfy all of the inclusion/exclusion criteria will be randomized 1:1 to receive either EWO1, or placebo for 28 days. After the treatment-period, patients will be followed for 14 days to see if there is any rebound in rhinitis symptoms. The Primary efficacy endpoint is weekly combined symptom scores at the end of treatment. Besides, intent to treat analyses will be carried out for both efficacy and safety. A minimum of 60 patients will be randomized into this two-treatment parallel-design study.


60 estimated patients




12+ years old


No Healthy Volunteers

Inclusion criteria

  • Male or female patients, aged 12 years and above
  • AR confirmed by positive allergen (dust mite; Dp) specific IgE ≧ 2+ within 12 months of enrollment
  • History of persistent moderate to severe allergic rhinitis
  • One or more of the following: abnormal sleep; impairment of daily activities, sports, leisure; problems caused at work or school; and/or troublesome symptoms.
  • Total nasal symptom scores (nasal rhinorrhea, nasal congestion, nasal itching, sneezing and post-nasal drip) ≧ 5 at baseline period (scale 0 : none; 1 : mild; 2 : moderate; 3 : severe)
  • No initiation of immunotherapy within 6 months or no dose change in immunotherapy for 1 month
  • Signed informed consent obtained prior to inclusion into the study

Exclusion criteria

  • History of recent (within 6 months) asthma
  • Chronic or intermittent use of inhaled, oral, intramuscular (i.m.), intravenous (i.v.), and/or potent/superpotent topical steroids within 2 weeks
  • Use of prohibited medicines within 2 weeks
  • Use of long-acting antihistamines within 2 weeks
  • Documented evidence of acute or significant chronic sinusitis
  • Chronic use of concomitant medications that could interfere with assessment
  • Known or suspected hypersensitivity to any of the herbal components in EWO1
  • Rhinitis medicamentosa
  • Planned travel outside the study area for a substantial portion of time during the study
  • Use of another investigational product within the past 30 days
  • Pregnant or lactating women; women of child-bearing potential must use adequate contraception.
  • Renal dysfunction as evidenced by creatinine level of 1.5 x upper limit of normal (ULN)
  • Liver dysfunction as evidenced by SGPT of > 1.5 x ULN
  • Signs and symptoms of upper respiratory infection (URI) upon admission

Trial design

Primary purpose




Interventional model

Parallel Assignment


Double Blind

Trial contacts and locations



Central trial contact

Min-Chien Yu, Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems